Beacon Therapeutics reported pivotal Phase 2/3 results for laruparetigene zovaparvovec in X-linked retinitis pigmentosa, with the trial meeting the FDA-endorsed primary endpoint in the low-luminance visual acuity (LLVA) scale. Beacon said responders achieved clinically meaningful gains versus an untreated control. The data move the program closer to a biologics license application filing and add momentum to the segment’s evolving competitive landscape, where late-stage efficacy and durable visual-function endpoints are driving investor focus on “next-wave” inherited retinal therapies.